Edwin Wagena, currently serving as the Chief Operating Officer of the company, will take over as the new CEO. Edwin is an accomplished senior executive with over 20 years’ experience in the cell therapy sector and in clinical development in general. Since 2008, he has specialised in the development of ATMPs and orphan drugs, and has designed and managed the European and North-American regulatory strategy and development program for several innovative therapies, including those in late-stage clinical trials.
Steve Docksey, Executive Chairman of Atelerix commented: “The company is building on a foundation of outstanding technology and exciting commercial opportunities, the result of excellent work by the team led by Mick. On behalf of the Board and Shareholders, I would like to thank Mick for his excellent leadership of the company since its formation and we look forward to his continuing role with the company. We are delighted that Edwin will be stepping into the CEO role and particularly at a time when advanced therapeutics are providing strong expansion opportunities for Atelerix. Edwin’s knowledge of clinical and process/product development of cell-based therapies as well as their manufacturing will be vital to our expansion. In addition, his leadership experience combined with strong organisational and operational skills will be a real asset as the company executes its multi-faceted growth plans.”
Dr Edwin Wagena, CEO Atelerix commented: “I am really excited to lead the team at Atelerix as we pursue our revenue growth objectives in the Discovery markets as well as expanding to new business opportunities linked to cell-based therapeutics and the collection of viruses and delivery of related therapies.”
For more information on the Atelerix cell encapsulation technology, please visit www.atelerix.co.uk or please contact:
CEO, Atelerix Ltd
Tel: +44 (0)191 580 6181
Email: [email protected]
About Atelerix Ltd
Atelerix is a UK-based company whose patented technology is transforming the storage and transport of living cells by enabling extended storage at temperatures between 4°C and 25°C while preserving their functional viability. The company’s customers are developing cell-based therapeutics, cell lines, organoids and assays for use in drug discovery and development. Atelerix products eliminate the need for complex ultra-low temperature logistics and potentially harmful freeze-thaw processes, providing greater quality, consistency of performance, flexibility, convenience and security as critical samples are shipped around the world.